Format

Send to

Choose Destination
Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29.

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Author information

1
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA xgao4@partners.org.
2
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
3
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center